Genmab — April 2024
-
Genmab indledes med "underperform" hos amerikansk børshus
2.4.2024 06.41 • MarketWire •Genmab har fået indledt dækningen hos amerikanske Bernstein med den negative anbefaling "underperform" og et kursmål på 1662 kr.
Det fremgår af Bloomberg News.
Kursmålet afspejler et negativt potentiale 20,3 pct. i forhold til lukkekursen onsdag. Her faldt Genmab-aktien 2,0 pct. til 2084 kr.
.\˙ MarketWire
Morten Frederik Heltoft
-
Transactions in Connection with Share Buy-back Program https://www.proinvestor.com/investornyt/1139200/transactions-in-connection-with-share-buy-back-program
-
It seems there are two distinct different analyst schools - one that believes in opt-in and another that does not. Believers have ~3k targets non believers have sub 2k targets
-
Hard to tell from the publicly available information.
-
Godmorgen
-
C25: Oversigt over regnskabsforventninger https://www.proinvestor.com/boards/119651
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind